**Hepatocellular Carcinoma**

- **Localized**
  - No Prior Therapy
    - 1st Line
      - IRB #2377: A humanitarian device exemption use protocol of TheraSphere for treatment of unresectable Hepatocellular Carcinoma
    - 2nd Line or more
      - IRB #20410: A Phase 3, Randomized, Open-Label Study of Atezolizumab plus Bevacizumab vs. Active Surveillance as Adjuvant Therapy in Patients with Hepatocellular Carcinoma at High Risk of Recurrence after Surgical Resection or Ablation
      - IRB #20744: Pembrolizumab + Lenvatinib + TACE (Transarterial Chemoembolization) vs Placebo + TACE in Intermediate Stage HCC

- Prior Therapy
  - 1st Line
    - IRB #22443: A Phase 2, Multicenter, Clinical Study to Evaluate the Safety and Efficacy of MK-1308A (Coformulated MK-1308/MK-3475) in Combination with Lenvatinib (E7080/MK-7902) in First-line Therapy of Participants with Advanced/Unresectable Biliary Tract Carcinoma
  - 2nd Line
    - IRB #20506: A Phase 3, Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced/Unresectable Biliary Tract Carcinoma
    - IRB #20357: [NCI CIRB] A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
    - IRB #16033: Phase II study of induction systemic mFOLFIROX followd by hepatic arterial infusion of Fluorouridine and Dexamethasone given concurrently with systemic mFOLFIRI as a first-line therapy in patients with unresectable liver-dominant intrahepatic cholangiocarcinoma

**Cholangiocarcinoma**

- 1st Line or 2nd Line
  - IRB #19095: A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)

**CROSS-DISEASE TRIALS:**

- IRB# TBD: EAY131 (MATCH)

3/1/2021

http://www.ohsu.edu/research/rda/so/knight.php